$CORT News

Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Corcept Therapeutics Refiles Its New Drug Application With Additional Analyses Of Data To FDA For Relacorilant To Treat Cushing's Syndrome

Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT)

CORT Stock Rises 42% in a Month: Here's What You Should Know

Reported Saturday, CATALYST Trial Data Show Korlym Reduces HbA1c By 1.3% And Body Weight By 5.1 Kg In Hypercortisolism Patients With Difficult-To-Control Diabetes

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

Corcept Therapeutics Discloses Amended Complaint Filed By Former Employee, Will Defend Itself Against Claims

Corcept Therapeutics Announces New Overall Survival Data From Its Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel In An Oral Presentation At The ASCO 2026; Patients Treated With Lifyorli Combined With Nab-Paclitaxel Experienced A 35 Percent Reduction In The Risk Of Death Compared To Patients Treated With Nab-paclitaxel Alone

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $95

Corcept Therapeutics To Resubmit Its New Drug Application To FDA For Relacorilant To Treat Cushing's Syndrome Patients

UBS Upgrades Corcept Therapeutics to Buy, Raises Price Target to $72

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $75

Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $88

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript